AMGN קפיטליזציה חשבונאית Amgen

Risks for Amgen Inc. (AMGN) are centered on the loss of exclusivity for legacy formulas and government price controls, which are offset by a strong pipeline. Amidst fierce competition from low-cost generics, the company is betting on the acquisition of innovative startups, and the indicator stands at 11.74. The stock's price history complements data regarding the ownership of high-tech plants across various regions, ensuring the stability of biologic production.

Book value capitalization measures the total value of Amgen Inc. (AMGN) net assets minus all debt obligations. This indicator allows for an assessment of the business's real value, stripped of leveraged capital. The current book value confirms the financial stability of the biopharmaceutical behemoth. Stable demand for life-saving drugs ensures a constant cash flow, which minimizes volatility risks and guarantees capital protection during economic downturns.